Joshua Cohen

The Trump administration has made bold claims about how much GLOBE and GUARD models will save Medicare. But most of those vanish once the exemptions are accounted for.

NHS hasn’t budgeted for the spending increase entailed by the U.S.-U.K. deal to allow payment for more drugs while keeping funding levels constant for other healthcare.

The question becomes whether firms will respond by withdrawing drugs from certain markets or delaying launches of their newly approved drugs in these jurisdictions.

While Pharmacy First could partially relieve wait times at GP offices and emergency rooms, it’s sidestepping the larger chronic problem of NHS underfunding.

With Medicare Advantage premiums to drop by 16% in 2027, this could further boost the percentage of seniors and disabled folks who choose the privately run alternative.

Given what some experts and clinicians cite as a lack of clear evidentiary benefit, FDA approval doesn’t guarantee reimbursement of multi-cancer early detection tests.

Continued progress against cancer will require collaboration among all key stakeholders. To this end, more stable and sustained federal investment is essential.

Besides increases in premiums, deductibles and patient cost-sharing, tens of millions of Americans have medical debt. Medical debt is even a problem the insured.

With the rise in certain medical expenses not included in the CPI, it’s evident that out-of-pocket healthcare costs are enhancing an already growing affordability crisis.

It’s expected that 2027 will see the largest spike in recent memory of the numbers of un- and underinsured individuals in the United States.